Investigation on effect of mixed herbal medicines (fennel,chamomile,saffron) on menopausal syndrome,hormonal changing and quality of life

Investigation on effect of mixed herbal medicines (fennel,chamomile,saffron)on menopausal syndrome and hormonal changing and quality of life in menopausal women in Mashhad with 4 groups in different doses and placebo controlled

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016092429950N1

Enrollment

120

Registered

2017-05-29

Start date

2016-04-29

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause. is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. This is the American ICD-10-CM version of N95.1. Other international versions of ICD-10 N95.1 may differ.

Interventions

Intervention 1: Group 1 low dose: 250 mg chamomile+30 mg fennel+15 mg saffron ,25 drops daily. Intervention 2: Group 2 high dose: 1000 mg chamomile+120 mg fennel+60 mg saffron,25 drops daily. Interve

Treatment - Drugs

Group 1 low dose: 250 mg chamomile+30 mg fennel+15 mg saffron ,25 drops daily

Group 2 high dose: 1000 mg chamomile+120 mg fennel+60 mg saffron,25 drops daily

Group 3 placebo:sterile dH2O,25 drops daily

Group 4 intermediate dose : 500 mg chamomile+60 mg fennel+30 mg saffron,25 drops daily

Eligibility

Sex/Gender

Female

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: lack of menstruation in last 12 months; having tested showed the evidence of menopause; having menopausal syndrome; the range of the age is between 45 - 65 years. Exclusion criteria : using anti-anxiety drugs; using antidepressants; using hormones such as: estrogen and progesterone in the last 6 months; using anticoagulant and NSAIDs such as: ibuprofen; having asthma and allergies; thyroid diseases; psychosomatic disorders; pheochromocytoma; carcinoma; leukemia; cancer; lack of proper use of herbal medicines in this study; creating skin irritation and allergy drug.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Depression. Timepoint: at the beginning,6 weeks later and 12 weeks later at the end of intervention. Method of measurement: Beck questioner.;Insomnia. Timepoint: at the beginning,6 weeks later and 12 weeks later at the end of intervention. Method of measurement: ISI questioner.	—

Primary

Measure	Time frame
Menopausal syndrome. Timepoint: At the beginning of the study,6 weeks later and 12 weeks later at the end of intervention. Method of measurement: Menopause Rating Scale (MRS).;Quality of life. Timepoint: At the beginning of the study,6 weeks later and 12 weeks later at the end of intervention. Method of measurement: Quality of life questioner(QOL).;Hormones changes. Timepoint: At the beginning of the study and 12 weeks later at the end of intervention. Method of measurement: Laboratory measurements.	—

Measure

Time frame

Menopausal syndrome. Timepoint: At the beginning of the study,6 weeks later and 12 weeks later at the end of intervention. Method of measurement: Menopause Rating Scale (MRS).;Quality of life. Timepoint: At the beginning of the study,6 weeks later and 12 weeks later at the end of intervention. Method of measurement: Quality of life questioner(QOL).;Hormones changes. Timepoint: At the beginning of the study and 12 weeks later at the end of intervention. Method of measurement: Laboratory measurements.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Khadije Mirzaii

Mashhad university of medical science

mirzaiikh@mums.ac.ir+51 38591513

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026